Skip to Content

Phathom Pharmaceuticals, Inc.

Company NamePhathom Pharmaceuticals, Inc.
Stock SymbolPHAT

On August 2, 2022, Phathom disclosed that it had “detected trace levels of a nitrosamine in vonoprazan drug product in [its] post-approval testing as [it] prepared for commercial launch.” As a result, the Company planned to seek approval for additional testing methods and controls “to address this impurity prior to releasing [its] first vonoprazan-based products to the market.” The Company also stated that this will result in a delay of planned product launches.

On this news, Phathom’s stock fell $2.61, or 28.8%, to close at $6.46 per share on August 2, 2022, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Phathom Pharmaceuticals, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd